In The Media
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH.
Biol Psychiatry 2000; 47(4); 351-4
This landmark 2000 Yale study documented ketamine’s remarkable antidepressive effects, and launched the movement to provide ketamine as a treatment option for those with refractory mood and anxiety disorders.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK
Arch Gen Psychiatry. 2006 Aug;63(8):856-64.
Led by NIMH’s Dr. Carlos Zarate, the study found that an impressive 71% of participants felt better the day after taking ketamine, and 35% still felt better a week later. None had responded previously to standard antidepressant drugs or electroshock therapy, and none improved when dosed with a placebo.
This website provides a wealth of candid information about ketamine, the infusion experience, and links to local doctors, trials, and clinics. Founded at the National Institutes of Health in 2012 by ketamine clinical trial volunteers, the group advocates for affordable, widespread access to ketamine therapy.